Dementia and Alzheimer Disease

These apps are designed to improve treatment adherence, language skills, symptom tracking, communication, and other helpful functions.

A dementia expert addresses current controversies on proton pump inhibitors.

Here is evidence that metformin, especially at high doses and for long periods, is associated with increased risk for neurodegenerative diseases and dementia.

These mobile apps provide tools to record medication details and reminders, first aid instructions, step-by-step recovery guides, and other topics of concern for you and your patient.

Medications to treat dementia can improve behavioral symptoms, but have risks. Music therapy, however, offers a low-cost, nonpharmacological option.

Studies discussed include neuropsychiatric symptoms leading to mild cognitive impairment and gesture comprehension and language in children with autism.

Studies examined the impact of blood pressure trajectories on dementia risk and explored the relationship between sleep apnea and Aβ accumulations.

May news includes ground-breaking FDA approvals, predictions of Alzheimer disease, and a possible biomarker for mild traumatic brain injury.

From the first hand-held vagus nerve stimulator for episodic cluster headache to a TMS therapy system for depression, we highlight 5 new technologies.

April news includes tools to manage brain injury and predict recovery, new drug hits and misses, and an updated epilepsy classification system.

March news includes possible brain tumor therapies, a study exploring mechanisms underlying demyelination-induced seizures, and VNS post stroke.

Ten general and disease-specific apps for neurologists include assessment scales, anatomical diagrams, and interactive clinical decision support.

Research included the impact of diet on cognitive decline and the degree of a link between depression & dementia post intracerebral hemorrhage.

February news includes stroke risk with Alzheimer disease & migraine, neonatal hemorrhagic stroke, and head trauma in sports.

Although sauna bathing can be beneficial in cardiovascular disease, how does the practice impact dementia and Alzheimer disease?

January news includes the first FDA-approved drug for spinal muscular atrophy, various epilepsy treatments & vitamin D’s impact on Alzheimer & headache.

Could marijuana use increase the risk of developing Alzheimer disease?

From Alzheimer disease to Zika virus, we’ve compiled a list of this year’s most popular articles on Neurology Times.

Research from AES 2016 explored relationships between epilepsy and other neurological disorders, including Alzheimer disease, MS, stroke, and autism.

November news includes the first human clinical trial focusing on tau in Alzheimer disease and Zika-related microcephaly not presenting at birth.

Is loneliness predictive of preclinical Alzheimer disease? Dr. Lazzara discusses a study of cortical amyloid burden and loneliness in older adults.

November news includes potential Alzheimer treatments, FDA approval of a device to prevent recurrent stroke, & a newly typified headache disorder.

Dr. Lazzara reports on a study examining the effects of exercise on the cognitive function of older adults with mild cognitive impairment.

Oct. news includes an approved deep brain stimulation system for movement disorders & biomarkers that improve risk assessment in atrial fibrillation.

Dr. Bobby Lazzara reports on a clinical trial of aducanumab, a human monoclonal antibody, in patients with prodromal or mild Alzheimer disease.

Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.

Why is a lower BMI linked to greater dementia risks in the elderly? Dr. Bobby Lazzara discusses a recent analysis using the Harvard Aging Brain Study.

Our August news includes a potential classification system for Alzheimer disease, new findings in a 3D model of TBI, and migraine treatments.

Recent neurological studies outline a link between TBI and Parkinson disease, discuss neuroimaging to predict recovery, and warn against DIY tDCS.

Dr. Bobby Lazzara discusses the first description of reversal of cognitive decline in early Alzheimer disease or its precursors.